Metagenomi Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 11, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 11, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Item 5. Other Information.
There have been no material changes to the procedures by which security holders may recommend nominees to the Company’s Board since the Company last provided disclosure in response to the requirements of Item 407(c)(3) of Regulation S-K.
Brian C. Thomas, Ph. D., founder and member of our Board of Directors, entered into a pre-arranged stock trading plan on February 10, 2026. Dr. Thomas’s trading plan provides for the sale of up to 110,000 shares of our common stock between May 1, 2026 (subject to compliance with applicable laws relating to the timing for commencement of sales under Rule 10b5-1) and May 3, 2027, subject to certain minimum price thresholds. This trading plan is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act.
During the quarter ended March 31, 2026, no other director or “officer” of the Company, as defined in Rule 16a-1(f) under the Exchange Act, adopted orterminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.